ABOUT SIMR
Company Profile
Management Team
SAB
Vision & Mission
Milestones
Investors
R&D
Research Focus
Pipeline
Translational Center
MEDIA
Expanded Access Policy
Press Releases
PARTNER
Business Development
Research Cooperation
JOIN US
CONTACT
中文
|
EN
ABOUT SIMR
Company Profile
Management Team
SAB
Vision & Mission
Milestones
Investors
R&D
Research Focus
Pipeline
Translational Center
MEDIA
Expanded Access Policy
Press Releases
PARTNER
Business Development
Research Cooperation
JOIN US
CONTACT
中文
EN
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Home
>
ABOUT SIMR
>
Milestones
>
2024
2024
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
In May, SR750 received Orphan Drug Designation from the U.S. FDA for the treatment of trigeminal neuralgia.
发布时间：2025年12月17日
上一篇：无
下一篇：暂无
